Pharvaris (PHVS) Competitors $17.59 -0.89 (-4.82%) As of 02:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHVS vs. AKRO, MRUS, MOR, SRRK, PTGX, CRNX, SWTX, OGN, CPRX, and VKTXShould you be buying Pharvaris stock or one of its competitors? The main competitors of Pharvaris include Akero Therapeutics (AKRO), Merus (MRUS), MorphoSys (MOR), Scholar Rock (SRRK), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), SpringWorks Therapeutics (SWTX), Organon & Co. (OGN), Catalyst Pharmaceuticals (CPRX), and Viking Therapeutics (VKTX). These companies are all part of the "pharmaceutical products" industry. Pharvaris vs. Akero Therapeutics Merus MorphoSys Scholar Rock Protagonist Therapeutics Crinetics Pharmaceuticals SpringWorks Therapeutics Organon & Co. Catalyst Pharmaceuticals Viking Therapeutics Pharvaris (NASDAQ:PHVS) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment, analyst recommendations and community ranking. Which has better earnings & valuation, PHVS or AKRO? Akero Therapeutics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharvarisN/AN/A-$109.18M-$2.68-6.56Akero TherapeuticsN/AN/A-$151.76M-$3.75-12.17 Does the MarketBeat Community favor PHVS or AKRO? Akero Therapeutics received 80 more outperform votes than Pharvaris when rated by MarketBeat users. However, 67.27% of users gave Pharvaris an outperform vote while only 65.36% of users gave Akero Therapeutics an outperform vote. CompanyUnderperformOutperformPharvarisOutperform Votes3767.27% Underperform Votes1832.73% Akero TherapeuticsOutperform Votes11765.36% Underperform Votes6234.64% Does the media favor PHVS or AKRO? In the previous week, Akero Therapeutics had 6 more articles in the media than Pharvaris. MarketBeat recorded 13 mentions for Akero Therapeutics and 7 mentions for Pharvaris. Akero Therapeutics' average media sentiment score of 1.18 beat Pharvaris' score of 0.82 indicating that Akero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Akero Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is PHVS or AKRO more profitable? Akero Therapeutics' return on equity of -32.46% beat Pharvaris' return on equity.Company Net Margins Return on Equity Return on Assets PharvarisN/A -38.52% -36.69% Akero Therapeutics N/A -32.46%-29.83% Do analysts rate PHVS or AKRO? Pharvaris currently has a consensus target price of $39.00, suggesting a potential upside of 121.73%. Akero Therapeutics has a consensus target price of $76.29, suggesting a potential upside of 67.11%. Given Pharvaris' higher possible upside, research analysts plainly believe Pharvaris is more favorable than Akero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pharvaris 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, PHVS or AKRO? Pharvaris has a beta of -2.84, suggesting that its share price is 384% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.18, suggesting that its share price is 118% less volatile than the S&P 500. SummaryAkero Therapeutics beats Pharvaris on 7 of the 12 factors compared between the two stocks. Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHVS vs. The Competition Export to ExcelMetricPharvarisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$915.55M$6.74B$5.50B$7.96BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-6.257.3822.6318.55Price / SalesN/A241.88397.30103.38Price / CashN/A65.8538.1834.62Price / Book2.216.476.704.25Net Income-$109.18M$143.68M$3.23B$248.27M7 Day Performance11.11%1.85%1.36%1.28%1 Month Performance18.60%6.73%3.85%3.75%1 Year Performance-28.41%-2.72%15.87%5.31% Pharvaris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHVSPharvaris2.0173 of 5 stars$17.59-4.8%$39.00+121.7%-24.8%$915.55MN/A-6.2530Analyst ForecastAnalyst RevisionNews CoverageAKROAkero Therapeutics3.7969 of 5 stars$37.67+0.1%$76.29+102.5%+129.3%$3.00BN/A-10.0530Insider TradeNews CoveragePositive NewsMRUSMerus3.4307 of 5 stars$43.23+0.4%$85.31+97.3%+1.3%$2.99B$36.13M-10.9437Upcoming EarningsAnalyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730SRRKScholar Rock4.0551 of 5 stars$29.81-3.1%$42.67+43.1%+124.3%$2.83B$33.19M-12.69140Upcoming EarningsInsider TradeNews CoveragePositive NewsPTGXProtagonist Therapeutics3.4698 of 5 stars$45.80-1.0%$65.44+42.9%+82.5%$2.81B$434.43M17.22120Upcoming EarningsNews CoveragePositive NewsCRNXCrinetics Pharmaceuticals3.6563 of 5 stars$30.15-0.9%$73.00+142.1%-23.8%$2.81B$1.04M-8.08210Upcoming EarningsNews CoveragePositive NewsSWTXSpringWorks Therapeutics1.9492 of 5 stars$37.06-2.3%$73.20+97.5%-0.8%$2.78B$191.59M-10.65230Analyst ForecastNews CoverageOGNOrganon & Co.4.7633 of 5 stars$10.67-4.0%$20.60+93.1%-30.5%$2.75B$6.40B3.2010,000Earnings ReportOptions VolumeNews CoverageGap DownCPRXCatalyst Pharmaceuticals4.6817 of 5 stars$22.02-2.2%$32.29+46.6%+61.4%$2.69B$491.73M18.6680Upcoming EarningsNews CoveragePositive NewsVKTXViking Therapeutics4.4974 of 5 stars$23.72-0.9%$89.75+278.4%-63.7%$2.66BN/A-23.7220Analyst ForecastOptions VolumeAnalyst Revision Related Companies and Tools Related Companies Akero Therapeutics Alternatives Merus Alternatives MorphoSys Alternatives Scholar Rock Alternatives Protagonist Therapeutics Alternatives Crinetics Pharmaceuticals Alternatives SpringWorks Therapeutics Alternatives Organon & Co. Alternatives Catalyst Pharmaceuticals Alternatives Viking Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHVS) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PHVS Stock Free PHVS Stock Alerts